title: Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).
abstract: N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of topoisomerase II, capable of preventing topoisomerase II activity on DNA. The concentration of AD 288 required to inhibit the topoisomerase II-catalyzed decatenation of linked networks of kinetoplast DNA was comparable to that for DOX. However, AD 288 did not stabilize cleavable complex formation or stimulate topoisomerase II-mediated DNA cleavage. In addition, AD 288 inhibited the formation of cleavable complexes by etoposide in a concentration-dependent manner. Human CCRF-CEM cells and murine J774. 2 cells exhibiting resistance against DOX, teniposide, or 3'-hydroxy-3'-deaminodoxorubicin through reduced topoisomerase II activity remained sensitive to AD 288. These studies suggest that AD 288 inhibits topoisomerase II activity by preventing the initial non-covalent binding of topoisomerase II to DNA. Since AD 288 is a potent DNA intercalator, catalytic inhibition is achieved by prohibiting access of the enzyme to DNA binding sites. These results also demonstrate that specific substitutions on the aminosugar of DOX can alter the mechanism of topoisomerase II inhibition.
authors.affiliation: Department of Pharmacology, University of Tennessee Health Science Center, 38163, USA, Memphis, TN, USA. llothstein@utmem.edu
authors.forename: L
authors.initials: L
authors.lastname: Lothstein
authors.forename: D P
authors.initials: DP
authors.lastname: Suttle
authors.forename: J B
authors.initials: JB
authors.lastname: Roaten
authors.forename: Y
authors.initials: Y
authors.lastname: Koseki
authors.forename: M
authors.initials: M
authors.lastname: Israel
authors.forename: T W
authors.initials: TW
authors.lastname: Sweatman
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002384:Catalysis; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D059005:Topoisomerase II Inhibitors; D005047:Etoposide; C062415:N-benzyladriamycin; D004317:Doxorubicin; D004247:DNA; D004250:DNA Topoisomerases, Type II